NTRBHealthcare · Biotechnology

NTRB Stock Forecast: Nutriband, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$6.96

+14.47% on the day

The 1 Wall Street analysts covering Nutriband, Inc. hold a median 12-month price target of $15 — +115.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 10 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$73.9M

Ticker Nerd rank

31 / 100

Median analyst target

$15

Analysts covering

Revenue$438K−29.7% y/y

Operating income−$891K

Net income−$881K

Free cash flow−$585K

Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown

Total return, dividends reinvested

+23.6%

+118.9%

YTD

+53.3%

+0.4%

From 52W high

−18.1%

From 52W low

+147.7%

$2.81

$8.50

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

NTRB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nutriband, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026

31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

Size

Growth

Issuance

Momentum

Revisions

Value

Volatility

Quality

Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NTRB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NTRB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $15Median $15High $15

The green dot is the last close — the median target sits +115.5% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
22 Jan 2025	Noble Capital Markets	Initiates	Outperform	$13
26 July 2022	Small Cap Consumer Research	Maintains	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTRB appears on the weeks it earns a place.

Performance

NTRB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Nutriband, Inc. returned +0.4% against +17.5% for the S&P 500, dividends included.

NTRB vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NTRB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Nutriband, Inc. (NTRB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −2.4×
Price / sales: 45.7×
Price / book: 13.9×
EV / EBITDA: −9.8×

Growth & margins

Revenue growth (YoY): −29.7%
Earnings growth (YoY): −29.7%
Gross margin: 41.6%
Operating margin: −203.6%
Net margin: 27.8%

Returns & dividend

Return on equity: −100.7%
Return on assets: −53.5%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Nutriband, Inc. (NTRB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Nutriband, Inc. has a market value of $73.9M and an enterprise value of $67.3M.
Revenue in the twelve months to 31 July 2026: $1.6M. The latest quarter shrank 29.7% year on year.
Net income over the same four quarters: −$7.0M, a −430.4% net margin.
Free cash flow in the twelve months to 31 July 2026: −$3.6M.
Shares outstanding: 12.2M.
Trailing P/E: −2.4×; forward P/E: −26.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Nutriband, Inc. employs 0 people.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

NTRB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
NTRBNutriband, Inc.	$73.9M	31
BSEMBioStem Technologies, Inc.	$74.5M	55
IBIOiBio, Inc.	$74.5M	26
TENXTenax Therapeutics, Inc.	$73.0M	23
CINGCingulate, Inc.	$75.2M	38
GANXGain Therapeutics, Inc.	$72.2M	31
YARWYarrow Bioscience, Inc.	$75.9M	56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nutriband, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NTRB news & analysis

Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit

GlobeNewsWire · 9 Sept 2026neutral

Nutriband announced that its CEO, Gareth Sheridan, will attend the inaugural Nasdaq LaB Biotech Summit on September 16. The announcement was made on September 9, 2026, via GlobeNewsWire.

Why it matters — NTRB watchers may see the CEO's attendance at a Nasdaq-hosted biotech summit as an opportunity for increased company visibility and networking within the life sciences sector.

Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

GlobeNewsWire · 8 Sept 2026positive

Nutriband received a Notice of Publication from the USPTO for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Once allowed, the company intends to submit the worldwide brand name to the FDA and other international regulatory agencies for approval.

Why it matters — This marks a step forward in trademark protection and regulatory preparation for Nutriband's lead product, signalling progress in advancing its abuse deterrent fentanyl patch toward market.

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

GlobeNewsWire · 13 Aug 2026neutral

Nutriband announced that its CEO and Co-Founder, Gareth Sheridan, will present at the 2026 Georgia Life Sciences Summit on Aug 26 as part of the CEO spotlight event. The announcement was made by the company on Aug 13, 2026.

Why it matters — The CEO's scheduled appearance at the summit provides NTRB watchers with visibility into the company's leadership engagement within the life sciences sector.

FAQ

Frequently asked questions about NTRB stock

What is the NTRB stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Nutriband, Inc. have a median 12-month price target of $15, with estimates ranging from $15 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NTRB stock a buy right now?

Of the 1 analysts covering Nutriband, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nutriband, Inc. 31 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NTRB?

As at 10 Sept 2026, Nutriband, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).

Will NTRB stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +115.5% from the last close, and Ticker Nerd's factor model ranks Nutriband, Inc. 31 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NTRB stock forecast for 2030?

No analyst covering Nutriband, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $15 over the next 12 months.

How has NTRB stock performed over the past year?

Nutriband, Inc. returned +0.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nutriband, Inc. do?

Nutriband Inc. is a pharmaceutical company focused on the development of transdermal drug delivery products.

What is the latest news on NTRB?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit". Nutriband announced that its CEO, Gareth Sheridan, will attend the inaugural Nasdaq LaB Biotech Summit on September 16. The announcement was made on September 9, 2026, via GlobeNewsWire.

Company

About Nutriband, Inc.

Nutriband Inc. is a pharmaceutical company focused on the development of transdermal drug delivery products. The company’s core work centers on abuse-deterrent patch technologies designed to reduce the risk of misuse, diversion, and accidental exposure for drugs with abuse potential, particularly opioids. Its lead development program is AVERSA Fentanyl, alongside additional transdermal products such as AVERSA Buprenorphine and AVERSA Methylphenidate. Nutriband also operates through business segments that include pharmaceuticals and medical devices, supporting both product development and related manufacturing activities. Based in Orlando, Florida, Nutriband serves the healthcare market by advancing patch-based therapies that aim to deliver medications through the skin in a controlled and convenient format.

CEO Mr. Gareth Sheridan · United States · https://www.nutriband.com